PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT 2.1 Preface 2.2 Preface 2.3 Currency conversion rates for US$ PART 03: MARKET LANDSCAPE Market ecosystem Market characteristics Market segmentation analysis PART 04: MARKET SIZING Market definition Market sizing 2018 Market size and forecast 2018-2023 PART 05: FIVE FORCES ANALYSIS Bargaining power of buyers Bargaining power of suppliers Threat of new entrants Threat of substitutes Threat of rivalry Market condition PART 06: MARKET SEGMENTATION BY APPLICATION Market segmentation by application Comparison by application Neuroinvasive - Market size and forecast 2018-2023 Non-neuroinvasive - Market size and forecast 2018-2023 Market opportunity by application PART 07: CUSTOMER LANDSCAPE PART 08: GEOGRAPHIC LANDSCAPE Geographic segmentation Geographic comparison North America - Market size and forecast 2018-2023 Europe - Market size and forecast 2018-2023 Asia - Market size and forecast 2018-2023 ROW - Market size and forecast 2018-2023 Key leading countries Market opportunity PART 09: DECISION FRAMEWORK PART 10: DRIVERS AND CHALLENGES Market drivers Market challenges PART 11: MARKET TRENDS Shifting epidemiology of Flaviviridae Rising awareness Growing risk of spreading infections via blood transfusions PART 12: VENDOR LANDSCAPE Overview Landscape disruption Competitive scenario PART 13: VENDOR ANALYSIS Vendors covered Vendor classification Market positioning of vendors Aurobindo Pharma Ltd. Bayer AG GlaxoSmithKline Plc Granules India Ltd. Johnson & Johnson Services Inc. Mylan NV Novartis AG Perrigo Co. Plc Pfizer Inc. Teva Pharmaceutical Industries Ltd. PART 14: APPENDIX Research methodology List of abbreviations Definition of market positioning of vendors PART 15: EXPLORE TECHNAVIO   Exhibit 01: Vendors: Key offerings Exhibit 02: Global pharmaceuticals market Exhibit 03: Segments of global pharmaceuticals market Exhibit 04: Market characteristics Exhibit 05: Market segments Exhibit 06: Market definition - Inclusions and exclusions checklist Exhibit 07: Market size 2018 Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions) Exhibit 09: Global market: Year-over-year growth 2019-2023 (%) Exhibit 10: Five forces analysis 2018 Exhibit 11: Five forces analysis 2023 Exhibit 12: Bargaining power of buyers Exhibit 13: Bargaining power of suppliers Exhibit 14: Threat of new entrants Exhibit 15: Threat of substitutes Exhibit 16: Threat of rivalry Exhibit 17: Market condition - Five forces 2018 Exhibit 18: Application - Market share 2018-2023 (%) Exhibit 19: Comparison by application Exhibit 20: Neuroinvasive - Market size and forecast 2018-2023 ($ millions) Exhibit 21: Neuroinvasive - Year-over-year growth 2019-2023 (%) Exhibit 22: Non-neuroinvasive - Market size and forecast 2018-2023 ($ millions) Exhibit 23: Non-neuroinvasive - Year-over-year growth 2019-2023 (%) Exhibit 24: Market opportunity by application Exhibit 25: Customer landscape Exhibit 26: Market share by geography 2018-2023 (%) Exhibit 27: Geographic comparison Exhibit 28: North America - Market size and forecast 2018-2023 ($ millions) Exhibit 29: North America - Year-over-year growth 2019-2023 (%) Exhibit 30: Top 3 countries in North America Exhibit 31: Europe - Market size and forecast 2018-2023 ($ millions) Exhibit 32: Europe - Year-over-year growth 2019-2023 (%) Exhibit 33: Top 3 countries in Europe Exhibit 34: Asia - Market size and forecast 2018-2023 ($ millions) Exhibit 35: Asia - Year-over-year growth 2019-2023 (%) Exhibit 36: Top 3 countries in Asia Exhibit 37: ROW - Market size and forecast 2018-2023 ($ millions) Exhibit 38: ROW - Year-over-year growth 2019-2023 (%) Exhibit 39: Top 3 countries in ROW Exhibit 40: Key leading countries Exhibit 41: Market opportunity Exhibit 42: Impact of drivers and challenges Exhibit 43: Vendor landscape Exhibit 44: Landscape disruption Exhibit 45: Vendors covered Exhibit 46: Vendor classification Exhibit 47: Market positioning of vendors Exhibit 48: Aurobindo Pharma Ltd. - Vendor overview Exhibit 49: Aurobindo Pharma Ltd. - Product segments Exhibit 50: Aurobindo Pharma Ltd. - Organizational developments Exhibit 51: Aurobindo Pharma Ltd. - Geographic focus Exhibit 52: Aurobindo Pharma Ltd. - Key offerings Exhibit 53: Aurobindo Pharma Ltd. - Key customers Exhibit 54: Bayer AG - Vendor overview Exhibit 55: Bayer AG - Business segments Exhibit 56: Bayer AG - Organizational developments Exhibit 57: Bayer AG - Geographic focus Exhibit 58: Bayer AG - Segment focus Exhibit 59: Bayer AG - Key offerings Exhibit 60: Bayer AG - Key customers Exhibit 61: GlaxoSmithKline Plc - Vendor overview Exhibit 62: GlaxoSmithKline Plc - Business segments Exhibit 63: GlaxoSmithKline Plc - Organizational developments Exhibit 64: GlaxoSmithKline Plc - Geographic focus Exhibit 65: GlaxoSmithKline Plc - Segment focus Exhibit 66: GlaxoSmithKline Plc - Key offerings Exhibit 67: GlaxoSmithKline Plc - Key customers Exhibit 68: Granules India Ltd. - Vendor overview Exhibit 69: Granules India Ltd. - Business segments Exhibit 70: Granules India Ltd. - Organizational developments Exhibit 71: Granules India Ltd. - Geographic focus Exhibit 72: Granules India Ltd. - Segment focus Exhibit 73: Granules India Ltd. - Key offerings Exhibit 74: Granules India Ltd. - Key customers Exhibit 75: Johnson & Johnson Services Inc. - Vendor overview Exhibit 76: Johnson & Johnson Services Inc. - Business segments Exhibit 77: Johnson & Johnson Services Inc. - Organizational developments Exhibit 78: Johnson & Johnson Services Inc. - Geographic focus Exhibit 79: Johnson & Johnson Services Inc. - Segment focus Exhibit 80: Johnson & Johnson Services Inc. - Key offerings Exhibit 81: Johnson & Johnson Services Inc. - Key customers Exhibit 82: Mylan NV - Vendor overview Exhibit 83: Mylan NV - Product segments Exhibit 84: Mylan NV - Organizational developments Exhibit 85: Mylan NV - Geographic focus Exhibit 86: Mylan NV - Segment focus Exhibit 87: Mylan NV - Key offerings Exhibit 88: Mylan NV - Key customers Exhibit 89: Novartis AG - Vendor overview Exhibit 90: Novartis AG - Business segments Exhibit 91: Novartis AG - Organizational developments Exhibit 92: Novartis AG - Geographic focus Exhibit 93: Novartis AG - Segment focus Exhibit 94: Novartis AG - Key offerings Exhibit 95: Novartis AG - Key customers Exhibit 96: Perrigo Co. Plc - Vendor overview Exhibit 97: Perrigo Co. Plc - Business segments Exhibit 98: Perrigo Co. Plc - Organizational developments Exhibit 99: Perrigo Co. Plc - Geographic focus Exhibit 100: Perrigo Co. Plc - Segment focus Exhibit 101: Perrigo Co. Plc - Key offerings Exhibit 102: Perrigo Co. Plc - Key customers Exhibit 103: Pfizer Inc. - Vendor overview Exhibit 104: Pfizer Inc. - Business segments Exhibit 105: Pfizer Inc. - Organizational developments Exhibit 106: Pfizer Inc. - Geographic focus Exhibit 107: Pfizer Inc. - Segment focus Exhibit 108: Pfizer Inc. - Key offerings Exhibit 109: Pfizer Inc. - Key customers Exhibit 110: Teva Pharmaceutical Industries Ltd. - Vendor overview Exhibit 111: Teva Pharmaceutical Industries Ltd. - Business segments Exhibit 112: Teva Pharmaceutical Industries Ltd. - Organizational developments Exhibit 113: Teva Pharmaceutical Industries Ltd. - Segment focus Exhibit 114: Teva Pharmaceutical Industries Ltd. - Key offerings Exhibit 115: Teva Pharmaceutical Industries Ltd. - Key customers Exhibit 116: Validation techniques employed for market sizing Exhibit 117: Definition of market positioning of vendors

Aurobindo Pharma Ltd. Bayer AG GlaxoSmithKline Plc Granules India Ltd. Johnson & Johnson Services Inc. Mylan NV Novartis AG Perrigo Co. Plc Pfizer Inc. Teva Pharmaceutical Industries Ltd.